论文部分内容阅读
目的:探讨放射性核素131I标记Rituximab及131I-Rituximab对B细胞淋巴瘤细胞进行放射免疫导向治疗的可行性。方法:采用氯胺-T法制备131I-Rituximab,采用CCK-8法观察131I-Rituximab对Raji细胞的抑制作用,对照组为131I、Rituximab组。结果:131I-Rituximab标记率在92%以上,放化学纯度达98%以上。CCK-8法表明131I-Rituximab对Raji细胞的抑瘤率与131I组和Rituximab组的抑瘤率有统计学差异(P<0.01)。结论:提示131I-Rituximab对人B细胞淋巴瘤的放射免疫导向治疗具有可行性。
Objective: To investigate the feasibility of radioimmunotherapy with 131I-labeled Rituximab and 131I-Rituximab for radioimmunotherapy of B-cell lymphoma cells. Methods: 131I-Rituximab was prepared by chloramine-T method and the inhibitory effect of 131I-Rituximab on Raji cells was observed by CCK-8 method. The control group was 131I, Rituximab group. Results: The labeling rate of 131I-Rituximab was above 92% and the radiochemical purity was above 98%. CCK-8 method showed that the inhibition rate of 131I-Rituximab on Raji cells was significantly different from that of 131I group and Rituximab group (P <0.01). Conclusion: The results suggest that 131I-Rituximab is feasible for radioimmunotherapy in human B-cell lymphoma.